Business Wire
02 Oct 2026, 06:30 UTC · 11h ago
Verdict
Headline takes no side. We score 4568 +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Daiichi Sankyo, AstraZeneca, and Summit Therapeutics entered a collaboration to evaluate Datroway in combination with ivonescimab across multiple tumor types.
Newpublished 2026-10-02 06:30 UTC
So whatExpanding the indicated use of Datroway into combination therapies could significantly expand the Total Addressable Market (TAM) for the drug's peak sales estimates.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The companies intend to start with a phase 3 trial in first-line triple negative breast cancer (TNBC).
Newpublished 2026-10-02 06:30 UTC
So whatPositive phase 3 data typically serves as the final regulatory hurdle before a BLA filing, potentially impacting revenue by late 2027 or 2028.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Entering a clinical trial collaboration to evaluate a key drug candidate across multiple tumor types.
More positive than 77% of ticker scores this week
Entering a clinical trial collaboration to evaluate a key drug candidate across multiple tumor types.
More positive than 77% of ticker scores this week
Entering a clinical trial collaboration to evaluate its drug ivonescimab in combination with Datroway.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
18h ago
More positive than 55% of relationship scores this week
[mutual] Daiichi Sankyo and Summit Therapeutics entered into a clinical trial collaboration agreement.
More positive than 6% of relationship scores this week
[mutual] Daiichi Sankyo and AstraZeneca are co-collaborators in a trial with Summit Therapeutics.
—
No price for 4568 right now — the quote feed didn't answer.
4568 chart →
